Romosozumab increases bone mineral density post-menopause

January 6, 2014
Romosozumab increases bone mineral density post-menopause
Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

(HealthDay)—Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

Michael R. McClung, M.D., from the Oregon Osteoporosis Center in Portland, and colleagues conducted a phase 2 study to examine the efficacy and safety of romosozumab over a 12-month period in 419 , aged 55 to 85 years of age, with low density. Participants were randomized to receive subcutaneous romosozumab every month (70, 140, or 210 mg) or every three months (140 or 210 mg), placebo, or an active comparator (70 mg weekly alendronate or 20 µg daily teriparatide).

The authors identified significant increases in bone mineral density at the lumbar spine with all dose levels of romosozumab, including a 11.3 percent increase with the 210-mg monthly dose, compared with a 0.1 percent decrease with placebo and 4.1 and 7.1 percent increases with alendronate and teriparatide, respectively. Large increases in bone mineral density were seen at the total hip and femoral neck, as well as transitory increases in markers with romosozumab, while sustained decreases were observed in a marker. Adverse events were similar between the groups, except for mild, generally nonrecurring injection-site reactions with romosozumab.

"Romosozumab was associated with increased and bone formation and with decreased bone resorption," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen and UCB Pharma, which funded the study.

Explore further: Bone mineral density tx can be effective for young CF patients

More information: Abstract
Full Text
Editorial

Related Stories

Bone mineral density tx can be effective for young CF patients

June 4, 2013
(HealthDay)—For children and young adults with cystic fibrosis, adequate calcium intake plus calcifediol can improve bone mineral density, while alendronate can increase bone mineral density for some non-responders, according ...

Alendronate reduces adjacent-level vertebral fractures

December 30, 2013
(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue of Spine.

New osteoporosis drug combination outperforms current alternatives

May 14, 2013
A combination of two FDA-approved osteoporosis drugs with different mechanisms of action was found to increase bone density better than treatment with either drug alone in a small clinical trial. As reported in paper receiving ...

Yearly zoledronic acid at lower-than-standard doses increases bone density

June 6, 2011
A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic ...

Overweight linked with reduced lung function in children with a history of early childhood wheezing

January 2, 2014
Overweight and obesity are significant risk factors for reduced lung function in school-aged children with a history of early childhood wheezing, according to a study carried out at the University of Eastern Finland. The ...

Osteoporosis drugs compared for side effects, efficacy

November 28, 2013
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic ...

Recommended for you

Novel therapies for multidrug-resistant bacteria

October 23, 2017
During this innovative study published in PLOS One, researchers found that novel classes of compounds, such as metal-complexes, can be used as alternatives to or to supplement traditional antibiotics, which have become ineffective ...

Key discoveries offer significant hope of reversing antibiotic resistance

October 23, 2017
Resistance to antibiotics is becoming increasingly prevalent and threatens to undermine healthcare systems across the globe. Antibiotics including penicillins, cephalosporins and carbapenems are known as β-lactams and are ...

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

Migraines may be the brain's way of dealing with oxidative stress

October 19, 2017
A new perspective article highlights a compelling theory about migraine attacks: that they are an integrated mechanism by which the brain protects and repairs itself. Recent insightful findings and potential ways to use them ...

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.